Before becoming LegalReader's Editor-in-Chief, Jay W. Belle Isle worked as a freelance copywriter with clients on four continents. Jay has a degree in Business Administration from Cleary University and a Juris Doctor from Thomas M. Cooley Law School. Jay has also worked as a contracts administrator for a DOD contractor specializing in vehicle armor.

Do as I Say, Not Who I Do: Anti-LGBTQ Rep. Wes Goodman Caught Having Gay Sex

Oh, hypocrisy… how I love you! Republican state representative Wes Goodman (87th District – OH), was elected last year after serving as aide to Jim Jordan, a very conservative, anti-LGBTQ Republican. Goodman, 33, didn’t last long in his position, though. The man people called the “conscience of the conservative movement” resigned recently over “inappropriate conduct.”

How to Make a Billion Dollars in the Pharmaceutical Industry

Our friends at recently published an excellent piece on the “profits before patients” paradigm and its impact on the opioid crisis in America, explaining steps Big Pharma takes to make mega-profits from unsuspecting patients. They have kindly offered to share an excerpt for our readers. A link to the complete article on their site appears at the end of this piece.

AbbVie Appeals $140M AndroGel Verdict

In early October, a Chicago federal jury reached a verdict in favor of Mr. Jeffrey Konrad in his suit against Big Pharma giant AbbVie, agreeing with Mr. Konrad’s allegations that the company’s testosterone replacement drug, AndroGel, caused his heart attack. The jury gave Mr. Konrad $140,000.00 in compensatory damages and $140M in punitive damages. AbbVie promised to appeal, and it made good on that promise just a few days ago.

Two Large Talc-Ovarian Cancer Verdicts Reversed

The latest happenings in the ongoing talc-ovarian cancer suits against Johnson & Johnson aren’t good news, particularly for two plaintiffs whose cases were already decided. The corporation recently succeeded in its efforts to have two of the larger verdicts (one of which is the largest verdict) reversed.

After Harvey, Texans Slammed by New Storm: Delayed Insurance Claims

You pay your premiums faithfully, are never late, and bought into the promises made by your home insurer that you would be protected in the event of an emergency. Along comes a hurricane of epic proportions – Harvey had 130mph sustained winds, an enormous storm surge, and dropped several feet of rain in a relatively short period – and you lose everything. “But,” you think, “at least I’m insured. Everything will be fine.” Sadly, that’s not proving to be the case for many people. Delayed insurance claims are the new storm slamming Texans.

Excerpt: Potential Pitfalls of a Bayer-Monsanto Merger

I was recently contacted by a fellow writer about a piece published on the potential Bayer-Monsanto merger. It’s such an excellent, and in-depth, look at the issue that I asked him if I could publish an excerpt here. He graciously agreed. This is a potential merger that has far-reaching and negative effects for us all. As the piece says, the Bayer-Monsanto merger is truly a marriage made in Hell.

Best Cities for Legal Professionals in 2017

Whether you’re soon to graduate law school and are looking for a place to start your career, or are simply looking for a change, one of the best things you can do for yourself is researching places you’d like to go. For some, it may be easy: moving closer to family or friends is a must. Others may simply want to go where the legal jobs are plentiful and the cost of living is affordable. Discovering your perfect place can take a lot of research. Fortunately, the good people at Abodo did that research for you.

Novo Nordisk Settled with DOJ for $58.65 Million over Victoza Diabetes Drug

Earlier this month, Dutch pharmaceutical company Novo Nordisk settled eight suits, brought by the Department of Justice, claiming that the company violated the Federal Food, Drug, and Cosmetic Act (FDCA) and the False Claims Act (FCA). The DOJ asserted that the company had misbranded its popular Type II diabetes drug, Victoza, by failing to comply with an “FDA-mandated Risk Evaluation and Mitigation Strategy (REMS).” The company agreed to the settlement of $58.65M. That amount includes disgorgement (repayment of illegally-earned profits) of $12.15M for the FDCA violations, which the DOJ claimed took place from 2010 to 2012, and a $46.5M payment for the FCA violations. The latter, according to the DOJ, took place from 2010 to 2014.